Dirozalkib (XZP-3621) vs Foritinib succinate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK / ROS1 · full Non-Small Cell Lung Cancer pipeline

Dirozalkib (XZP-3621)

Marketed by Xuanzhu Biopharmaceutical and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT05204628 · Phase 3 · status unknown

Patients were randomly assigned to XZP-3621 or crizotinib, but the study is open-label rather than blinded, which is a weaker design even though it measures a hard clinical outcome, progression-free survival, against an active standard-of-care comparator. Results have not been posted yet.

No aligned efficacy figure on record for this race.

Foritinib succinate

Developed by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT06569420 · Phase 3 · active, not recruiting

This was a randomized, actively-controlled (crizotinib) Phase 3 trial with 275 patients and a hard clinical primary endpoint (independently reviewed progression-free survival), and outside reporting indicates the trial clearly met this endpoint with a large PFS benefit favoring foritinib. However, the study was open-label with no blinding of patients or investigators, which limits confidence in outcome assessments that could be influenced by knowledge of treatment assignment, so it falls short of the highest evidence tier despite the favorable, statistically robust result.

Reported efficacy

Progression-free survival (PFS) by IRC (up to 36 months); Overall survival (OS) (up to 60 months); Progression-free survival (PFS) by INV (up to 36 months); Objective Response Rate (ORR) by IRC and INV (up to 36 months); Duration of response (DOR) by IRC and INV (up to 36 months); to evaluate the C-ORR in patient with CNS metastases. (up to 36 months); to assess the C-TTR in patient who have as CNS objective response (up to 36 months); to assess the C-DOR in patient who have as CNS objective response. (up to 36 months); to assess the C-TTP in patient who have as CNS objective response. (up to 36 months); The time to CNS progression in ITT by IRC. (up to 36 months); Incidence of adverse events. (up to 36 months); Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score (up to 36 months); Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire LC13 Score (up to 36 months): Phase III SAF-189s vs crizotinib trial (NCT06569420), primary endpoint IRC-assessed PFS: median not reached (SAF-189s/foritinib) vs 13.93 months (crizotinib); HR 0.23 (95% CI 0.14-0.38) (met)

Result source: NCT06569420

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDirozalkib (XZP-3621)Foritinib succinate
PFS, median—Not reported—Trial running · NCT06569420
OS, median—Not reported—Trial running · NCT06569420
ORR—Not reported—Trial running · NCT06569420
Duration of response, median—Not reported—Trial running · NCT06569420

PFS, median

Dirozalkib (XZP-3621)
—Not reported
Foritinib succinate
—Trial running · NCT06569420

OS, median

Dirozalkib (XZP-3621)
—Not reported
Foritinib succinate
—Trial running · NCT06569420

ORR

Dirozalkib (XZP-3621)
—Not reported
Foritinib succinate
—Trial running · NCT06569420

Duration of response, median

Dirozalkib (XZP-3621)
—Not reported
Foritinib succinate
—Trial running · NCT06569420
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Dirozalkib (XZP-3621): no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Foritinib succinate
Phase III SAF-189s vs crizotinib trial (NCT06569420), primary endpoint IRC-assessed PFS: median not reached (SAF-189s/foritinib) vs 13.93 months (crizotinib); HR 0.23 (95% CI 0.14-0.38) NCT06569420 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dirozalkib (XZP-3621)'s landscape · Foritinib succinate's landscape